Skip to main content
. Author manuscript; available in PMC: 2020 May 26.
Published in final edited form as: J Thorac Oncol. 2016 Sep 30;12(1):145–151. doi: 10.1016/j.jtho.2016.09.131

Figure 1.

Figure 1.

Pharmacokinetics of erlotinib and crizotinib administered in combination during cycle 1 of treatment. (A) Erlotinib exposure (by patient and geometric mean [geomean]) when administered alone (day 1) or in combination with crizotinib (days 1 and 15). (B) Crizotinib exposure on day 15. Circles indicate individual values, horizontal white lines indicate medians, boxes indicate 25th to 75th percentiles, and whiskers indicate 1.5 × interquartile range. AUCτ, area under the concentration– time curve over the dosing interval (crizotinib, 12 hours; erlotinib, 24 hours). aPfizer Inc., data on file.